The role of α-cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications

Endocrine Reviews

Volumn 28, Issue 3, 2007, Pages 253-283

  Dunning, Beth Elaine ^a   Gerich, John E ^b  

^a PharmaWrite   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 [[2 [[2 (2 CYANO 1 PYRROLIDINYL) 2 OXOETHYL]AMINO]ETHYL]AMINO]NICOTINONITRILE; ANTIDIABETIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BAY 27 995; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; FURIN; GASTRIN; GLUCAGON; GLUCAGON ANTIBODY; GLUCAGON DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 [206-214]; GLUCAGON RECEPTOR BLOCKING AGENT; GLUCAGON[1 N ALPHA TRINITROPHENYLHISTIDINE 12 HOMOARGININE]; GLUCOSE; HEPATOCYTE NUCLEAR FACTOR 3; HORMONE RECEPTOR BLOCKING AGENT; INSULIN; ISIS 148359; LIRAGLUTIDE; METFORMIN; MUSCARINIC M3 RECEPTOR; N [3 CYANO 6 (1,1 DIMETHYLPROPYL) 4,5,6,7 TETRAHYDRO 1 BENZOTHIEN 2 YL] 2 ETHYLBUTANAMIDE; NEUTRALIZING ANTIBODY; NNC 25 2504; PROTEIN; SOMATOSTATIN; SOMATOSTATIN DERIVATIVE; STIMULATORY GUANINE NUCLEOTIDE BINDING PROTEIN; SULFONYLUREA DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VILDAGLIPTIN;

CONTINUOUS INFUSION; DIET RESTRICTION; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; GLUCAGON BLOOD LEVEL; GLUCAGON RELEASE; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HOMEOSTASIS; HUMAN; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUTRIENT DYNAMICS; PANCREAS ISLET ALPHA CELL; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; STREPTOZOCIN DIABETES; TREATMENT OUTCOME;

ANIMALS; DIABETES MELLITUS, TYPE 2; FASTING; GLUCAGON; GLUCAGON-SECRETING CELLS; HUMANS; HYPERGLYCEMIA; POSTPRANDIAL PERIOD; RECEPTORS, GLUCAGON;

EID: 34250854205     PISSN: 0163769X     EISSN: 0163769X     Source Type: Journal    
DOI: 10.1210/er.2006-0026     Document Type: Review

References (307)

1. Banting FG, Best CH, Collip JB, Campbell WR, Fletcher AA 1991 Pancreatic extracts in the treatment of diabetes mellitus: preliminary report. 1922. CMAJ 145:1281-1286
2. Murlin JR, Clough HD, Gibbs CBF, Stokes AM 1923 Aqueous extracts of pancreas. I. Influence on the carbohydrate metabolism of depancreatized animals. J Biol Chem 56:253-296
3. Burger M, Brandt W 1935 Uber das glukagon (die hyperglykamisierende substanz des pankreas). Z Ges Exp Med 96:375-397
4. Staub A, Sinn L, Behrens OK 1955 Purification and crystallization of glucagon. J Biol Chem 214:619-632
5. Bromer WW, Sinn LG, Staub A, Behrens OK 1957 The amino acid sequence of glucagon. Diabetes 6:234-238
6. Elrick H, Witten TA, Arai Y 1958 Glucagon treatment of insulin reactions. N Engl J Med 258:476-480
7. Van Itallie TB, Felber JP, Hoet J, Renold AE 1959 Impaired glucose tolerance and glucosuria induced in man by repeated injections of glucagon. Diabetes 8:94-99
8. Yalow RS, Berson SA 1960 Immunoassay of endogenous plasma insulin in man. J Clin Invest 39:1157-1175
9. Unger RH, Eisentraut AM, McCall MS, Madison LL 1961 Glucagon antibodies and an immunoassay for glucagon. J Clin Invest 40:1280-1289
10. Unger RH, Ketterer H, Eisentraut AM 1966 Distribution of immunoassayable glucagon in gastrointestinal tissues. Metabolism 15:865-867
11. Bajorunas DR, Fortner JG, Jaspan JB 1986 Glucagon immunoreactivity and chromatographic profiles in pancreatectomized humans. Paradoxical response to oral glucose. Diabetes 35:886-893
12. Bringer J, Mirouze J, Marchal G, Pham TC, Luyckx A, Lefebvre P, Orsetti A 1981 Glucagon immunoreactivity and antidiabetic action of somatostatin in the totally duodeno-pancreatectomized and gastrectomized human. Diabetes 30:851-856
13. Mirsky IA, Perisutti G, Davis NC 1959 The destruction of glucagon by the blood plasma from various species. Endocrinology 64:992-1001
14. Weir GC, Turner RC, Martin DB 1973 Glucagon radioimmunoassay using antiserum 30K: interference by plasma. Horm Metab Res 5:241-244
15. Faloona GR, Unger RH 1974 Glucagon. In: Jaffe BM, Behrman HR, eds. Methods of hormone radioimmunoassay. New York: Academic Press; 317-330
16. Ahrén B, Lundquist I 1982 Glucagon immunoreactivity in plasma from normal and dystrophic mice. Diabetologia 22:258-263
17. Brazeau P, Vale W, Burgus R, Ling N, Butcher M, Rivier J, Guillemin R 1973 Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 179:77-79
18. Koerker DJ, Ruch W, Chideckel E, Palmer J, Goodner CJ, Ensinck J, Gale CC 1974 Somatostatin: hypothalamic inhibitor of the endocrine pancreas. Science 184:482-484
19. Mortimer CH, Tunbridge WM, Carr D, Yeomans L, Lind T, Coy DH, Bloom SR, Kastin A, Mallinson CN, Besser GM, Schally AV, Hall R 1974 Effects of growth-hormone release-inhibiting hormone on circulating glucagon, insulin, and growth hormone in normal, diabetic, acromegalic, and hypopituitary patients. Lancet 1:697-701
20. Johnston DG, Gill A, Hanson R, Alberti KG, Batstone G, Ørskov H1978 Somatostatin: a tool for investigation of the metabolic effects of cortisol and glucagon. Metabolism 27:1445-1447
21. Unger RH, Eisentraut AM, McCall MS, Madison LL 1962 Measurements of endogenous glucagon in plasma and the influence of blood glucose concentration upon its secretion. J Clin Invest 41: 682-689
22. Unger RH, Eisentraut AM, Madison LL 1963 The effects of total starvation upon the levels of circulating glucagon and insulin in man. J Clin Invest 42:1031-1039
23. Unger RH, Orci L 1981 Glucagon and the A cell: physiology and pathophysiology (first of two parts). N Engl J Med 304:1518-1524
24. Unger RH 1983 The Berson Memorial Lecture. Insulin-glucagon relationships in the defense against hypoglycemia. Diabetes 32: 575-583
25. Unger RH, Orci L 1975 The essential role of glucagon in the pathogenesis of diabetes mellitus. Lancet 1:14-16
26. Unger RH, Eisentraut AM 1964 Studies of the physiologic role of glucagon. Diabetes 13:563-568
27. Ohneda A, Parada E, Eisentraut AM, Unger RH 1968 Characterization of response of circulating glucagon to intraduodenal and intravenous administration of amino acids. J Clin Invest 47:2305-2322
28. Assan R, Rosselin G, Dolais J 1967 [The effects of perfusion and amino acid ingestion in glucagonenemia]. Journoes Annuelles de Diabetologie Hotel Dieu 7:25-41
29. Unger RH, Aguilar-Parada E, Muller WA, Eisentraut AM 1970 Studies of pancreatic α-cell function in normal and diabetic subjects. J Clin Invest 49:837-848
30. Muller WA, Faloona GR, Aguilar-Parada E, Unger RH 1970 Abnormal α-cell function in diabetes. Response to carbohydrate and protein ingestion. N Engl J Med 283:109-115
31. Unger RH, Ohneda A, Aguilar-Parada E, Eisentraut AM 1969 The role of aminogenic glucagon secretion in blood glucose homeostasis. J Clin Invest 48:810-822
32. Chiasson JL, Liljenquist JE, Sinclair-Smith BC, Lacy WW 1975 Gluconeogenesis from alanine in normal postabsorptive man. Intrahepatic stimulatory effect of glucagon. Diabetes 24:574-584
33. Magnusson I, Rothman DL, Gerard DP, Katz LD, Shulman GI 1995 Contribution of hepatic glycogenolysis to glucose production in humans in response to a physiological increase in plasma glucagon concentration. Diabetes 44:185-189
34. Stevenson RW, Steiner KE, Davis MA, Hendrick GK, Williams PE, Lacy WW, Brown L, Donahue P, Lacy DB, Cherrington AD 1987 Similar dose responsiveness of hepatic glycogenolysis and gluconeogenesis to glucagon in vivo. Diabetes 36:382-389
35. Cherrington AD 2001 Control of glucose production in vivo by insulin and glucagon. In: Jefferson LS, Cherrington AD, Goodman HM, eds. Handbook of physiology: a critical, comprehensive presentation of physiological knowledge and concepts. American Physiological Society. New York: Oxford University Press: 759-785
36. Woerle HJ, Szoke E, Meyer C, Dostou JM, Wittlin SD, Gosmanov NR, Welle SL, Gerich JE 2006 Mechanisms for abnormal postprandial glucose metabolism in type 2 diabetes. Am J Physiol Endocrinol Metab 290:E67-E77
37. Lecavalier L, Bolli G, Gerich J 1990 Glucagon-cortisol interactions on glucose turnover and lactate gluconeogenesis in normal humans. Am J Physiol 258:E569-E575
38. Wise JK, Hendler R, Felig P 1973 Influence of glucocorticoids on glucagon secretion and plasma amino acid concentrations in man. J Clin Invest 52:2774-2782
39. Wahren J, Felig P, Hagenfeldt L 1976 Effect of protein ingestion on splanchnic and leg metabolism in normal man and in patients with diabetes mellitus. J Clin Invest 57:987-999
40. Aguilar-Parada E, Eisentraut AM, Unger RH 1969 Effects of starvation on plasma pancreatic glucagon in normal man. Diabetes 18:717-723
41. Ahlborg G, Felig P, Hagenfeldt L, Hendler R, Wahren J 1974 Substrate turnover during prolonged exercise in man. Splanchnic and leg metabolism of glucose, free fatty acids, and amino acids. J Clin Invest 53:1080-1090
42. Felig P, Wahren J, Hendler R 1976 Influence of physiologic hyperglucagonemia on basal and insulin-inhibited splanchnic glucose output in normal man. J Clin Invest 58:761-765
43. Gerich JE, Lorenzi M, Hane S, Gustafson G, Guillemin R, Forsham PH 1975 Evidence for a physiologic role of pancreatic glucagon in human glucose homeostasis: studies with somatostatin. Metabolism 24:175-182
44. Sherwin RS, Hendler R, DeFronzo R, Wahren J, Felig P 1977 Glucose homeostasis during prolonged suppression of glucagon and insulin secretion by somatostatin. Proc Natl Acad Sci USA 74:348-352
45. Sherwin R, Wahren J, Felig P 1976 Evanescent effects of hypo- and hyperglucagonemia on blood glucose homeostasis. Metabolism 25:1381-1383
46. Gerich JE 2002 Hepatorenal glucose reciprocity in physiologic and pathologic conditions. Diabetes Nutr Metab 15:298-302
47. Woerle HJ, Meyer C, Popa EM, Cryer PE, Gerich JE 2003 Renal compensation for impaired hepatic glucose release during hypoglycemia in type 2 diabetes: further evidence for hepatorenal reciprocity. Diabetes 52:1386-1392
48. Cherrington AD, Chiasson JL, Liljenquist JE, Jennings AS, Keller U, Lacy WW 1976 The role of insulin and glucagon in the regulation of basal glucose production in the postabsorptive dog. J Clin Invest 58:1407-1418
49. Liljenquist JE, Mueller GL, Cherrington AD, Keller U, Chiasson J-L, Perry JM, Lacy WW, Rabinowitz D 1977 Evidence for an important role of glucagon in the regulation of hepatic glucose production in normal man. J Clin Invest 59:369-374
50. Muller MJ, Acheson KJ, Burger AG, Jequier E 1990 Evidence that hyperglycaemia per se does not inhibit hepatic glucose production in man. Eur J Appl Physiol Occup Physiol 60:293-299
51. Muller MJ, Moring J, Seitz HJ 1988 Regulation of hepatic glucose output by glucose in vivo. Metabolism 37:55-60
52. Cherrington AD, Liljenquist JE, Shulman GI, Williams PE, Lacy WW 1979 Importance of hypoglycemia-induced glucose production during isolated glucagon deficiency. Am J Physiol 236:E263-E271
53. Abs R, Verbist L, Moeremans M, Blockx P, De Leeuw I, Bekaert J 1990 Hypoglycemia owing to inappropriate glucagon secretion treated with a continuous subcutaneous glucagon infusion system. Acta Endocrinol (Copenh) 122:319-322
54. Assan R, Hautecouverture G, Guillemant S, Dauchy F, Protin P, Derot M 1969 [Evolution of hormonal parameters (glucagon, cortisol, growth hormone) and energetic parameters (glucose, fatty acids, free glycerol) in 10 severe cases of diabetic acido-ketosis under treatment]. Pathol Biol (Paris) 17:1095-1105
55. Muller WA, Faloona GR, Unger RH 1973 Hyperglucagonemia in diabetic ketoacidosis. Its prevalence and significance. Am J Med 54:52-57
56. Wiernsperger NF 2003 Oxidative stress: the special case of diabetes. Biofactors 19:11-18
57. Raskin P, Unger RH 1978 Effect of insulin therapy on the profiles of plasma immunoreactive glucagon in juvenile-type and adulttype diabetics. Diabetes 27:411-419
58. Borghi VC, Wajchenberg BL, Cesar FP 1984 Plasma glucagon suppressibility after oral glucose in obese subjects with normal and impaired glucose tolerance. Metabolism 33:1068-1074
59. Reaven GM, Chen YD, Golay A, Swislocki AL, Jaspan JB 1987 Documentation of hyperglucagonemia throughout the day in nonobese and obese patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 64:106-110
60. Hamaguchi T, Fukushima H, Uehara M, Wada S, Shirotani T, Kishikawa H, Ichinose K, Yamaguchi K, Shichiri M 1991 Abnormal glucagon response to arginine and its normalization in obese hyperinsulinaemic patients with glucose intolerance: importance of insulin action on pancreatic α-cells. Diabetologia 34:801-806
61. Gastaldelli A, Baldi S, Pettiti M, Toschi E, Camastra S, Natali A, Landau BR, Ferrannini E 2000 Influence of obesity and type 2 diabetes on gluconeogenesis and glucose output in humans: a quantitative study. Diabetes 49:1367-1373
62. Baron AD, Schaeffer L, Shragg P, Kolterman OG 1987 Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics. Diabetes 36:274-283
63. Basu R, Schwenk WF, Rizza RA 2004 Both fasting glucose production and disappearance are abnormal in people with "mild" and "severe" type 2 diabetes. Am J Physiol Endocrinol Metab 287:E55-E62
64. Raskin P, Aydin I, Yamamoto T, Unger RH 1978 Abnormal α-cell function in human diabetes: the response to oral protein. Am J Med 64:988-997
65. Toft-Nielsen MB, Damholt MB, Madsbad S, Hilsted LM, Hughes TE, Michelsen BK, Holst JJ 2001 Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 86:3717-3723
66. Aronoff SL, Bennett PH, Unger RH 1977 Immunoreactive glucagon (IRG) responses to intravenous glucose in prediabetes and diabetes among Pima Indians and normal Caucasians. J Clin Endocrinol Metab 44:968-972
67. Ohneda A, Watanabe K, Horigome K, Sakai T, Kai Y, Oikawa S 1978 Abnormal response of pancreatic glucagon to glycemic changes in diabetes mellitus. J Clin Endocrinol Metab 46:504-510
68. Gerich JE, Charles MA, Grodsky GM 1976 Regulation of pancreatic insulin and glucagon secretion. Ann Rev Physiol 38:353-388
69. Stagner JI, Samols E 1992 The vascular order of islet cellular perfusion in the human pancreas. Diabetes 41:93-97
70. Starke A, Imamura T, Unger RH 1987 Relationship of glucagon suppression by insulin and somatostatin to the ambient glucose concentration. J Clin Invest 79:20-24
71. Aguilar-Parada E, Eisentraut AM, Unger RH 1969 Pancreatic glucagon secretion in normal and diabetic subjects. Am J Med Sci 257:415-419
72. Unger RH 1976 The Banting Memorial Lecture 1975. Diabetes and the α-cell. Diabetes 25:136-151
73. Raskin P, Unger RH 1978 Glucagon and diabetes. Med Clin North Am 62:713-722
74. Hollander PM, Asplin CM, Palmer JP 1982 Glucose modulation of insulin and glucagon secretion in nondiabetic and diabetic man. Diabetes 31:489-495
75. Dimitriadis GD, Pehling GB, Gerich JE 1985 Abnormal glucose modulation of islet A- and B-cell responses to arginine in non-insulin-dependent diabetes mellitus. Diabetes 34:541-547
76. Raskin P, Aydin I, Unger RH 1976 Effect of insulin on the exaggerated glucagon response to arginine stimulation in diabetes mellitus. Diabetes 25:227-229
77. Ward WK, Bolgiano DC, McKnight B, Halter JB, Porte Jr D 1984 Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus. J Clin Invest 74:1318-1328
78. Gomis R, Novials A, Coves MJ, Casamitjana R, Malaisse WJ 1989 Suppression by insulin treatment of glucose-induced inhibition of insulin release in non-insulin-dependent diabetics. Diabetes Res Clin Pract 6:191-198
79. Franklin I, Gromada J, Gjinovci A, Theander S, Wollheim CB 2005 β-Cell secretory products activate α-cell ATP-dependent potassium channels to inhibit glucagon release. Diabetes 54:1808-1815
80. Diao J, Asghar Z, Chan CB, Wheeler MB 2005 Glucose-regulated glucagon secretion requires insulin receptor expression in pancreatic α-cells. J Biol Chem 280:33487-33496
81. Xu E, Kumar M, Zhang Y, Ju W, Obata T, Zhang N, Liu S, Wendt A, Deng S, Ebina Y, Wheeler MB, Braun M, Wang Q 2006 Intraislet insulin suppresses glucagon release via GABA-GABAA receptor system. Cell Metab 3:47-58
82. Gerich JE, Langlois M, Noacco C, Karam JH, Forsham PH 1973 Lack of glucagon response to hypoglycemia in diabetes: evidence for an intrinsic pancreatic α-cell defect. Science 182:171-173
83. Heller SR, Macdonald IA, Tattersall RB 1987 Counterregulation in type 2 (non-insulin-dependent) diabetes mellitus. Normal endocrine and glycaemic responses, up to ten years after diagnosis. Diabetologia 30:924-929
84. Bolli GB, Tsalikian E, Haymond MW, Cryer PE, Gerich JE 1984 Defective glucose counterregulation after subcutaneous insulin in noninsulin-dependent diabetes mellitus: paradoxical suppression of glucose utilization and lack of compensatory increase in glucose production, roles of insulin resistance, abnormal neuroendocrine responses, and islet paracrine interactions. J Clin Invest 73:1532-1541
85. Campbell LV, Kraegen EW, Meler H, Lazarus L 1979 Hormonal responses to insulin infusion in diabetes mellitus. Diabetologia 16:359-364
86. Meneilly GS, Cheung E, Tuokko H 1994 Counterregulatory hormone responses to hypoglycemia in the elderly patient with diabetes. Diabetes 43:403-410
87. Shamoon H, Friedman S, Canton C, Zacharowicz L, Hu M, Rossetti L 1994 Increased epinephrine and skeletal muscle responses to hypoglycemia in non-insulin-dependent diabetes mellitus. J Clin Invest 93:2562-2571
88. Hope KM, Tran PO, Zhou H, Oseid E, Leroy E, Robertson RP 2004 Regulation of α-cell function by the β-cell in isolated human and rat islets deprived of glucose: the "switch-off" hypothesis. Diabetes 53:1488-1495
89. Porte Jr D 1991 Banting lecture 1990. β-Cells in type II diabetes mellitus. Diabetes 40:166-180
90. Kahn SE 2000 The importance of the β-cell in the pathogenesis of type 2 diabetes mellitus. Am J Med 108(Suppl 6a):2S-8S
91. McCulloch DK, Raghu PK, Koerker DJ, Palmer JP, Klaff LJ 1989 Responses of the pancreatic A cell during hypoglycemia and hyperglycemia are dependent on the B cell. Metabolism 38:702-707
92. Bennett PH, Aronoff SL, Unger RH 1976 Evidence for an insulinin-dependent α-cell abnormality in human diabetes. Metabolism 25:1527-1529
93. Meier JJ, Kjems LL, Veldhuis JD, Lefebvre P, Butler PC 2006 Postprandial suppression of glucagon secretion depends on intact pulsatile insulin secretion: further evidence for the intraislet insulin hypothesis. Diabetes 55:1051-1056
94. Gosmanov NR, Szoke E, Israelian Z, Smith T, Cryer PE, Gerich JE, Meyer C 2005 Role of the decrement in intraislet insulin for the glucagon response to hypoglycemia in humans. Diabetes Care 28:1124-1131
95. Raju B, Cryer PE 2005 Loss of the decrement in intraislet insulin plausibly explains loss of the glucagon response to hypoglycemia in insulin-deficient diabetes: documentation of the intraislet insulin hypothesis in humans. Diabetes 54:757-764
96. Larsson H, Berglund G, Ahrén B 1995 Glucose modulation of insulin and glucagon secretion is altered in impaired glucose tolerance. J Clin Endocrinol Metab 80:1778-1782
97. Kirk RD, Dunn P, Smith JR, Beaven DW, Donald RA 1975 Abnormal pancreatic α-cell function in first-degree relatives of known diabetics. J Clin Endocrinol Metab 40:913-916
98. Berenson GS, Bao W, Srinivasan SR 1996 Abnormal characteristics in young offspring of parents with non-insulin-dependent diabetes mellitus. The Bogalusa Heart Study. Am J Epidemiol 144: 962-967
99. DeFronzo RA, Ferrannini E, Simonson DC 1989 Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake. Metabolism 38:387-395
100. DeFronzo RA, Bonadonna RC, Ferrannini E 1992 Pathogenesis of NIDDM. A balanced overview. Diabetes Care 15:318-368
101. DeFronzo RA 1997 Pathogenesis of type 2 diabetes: metabolic and molecular implications for identifying diabetes genes. Diabet Rev 5:177-269
102. Basu A, Shah P, Nielsen M, Basu R, Rizza RA 2004 Effects of type 2 diabetes on the regulation of hepatic glucose metabolism. J Investig Med 52:366-374
103. Natali A, Ferrannini E 2006 Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review. Diabetologia 49:434-441
104. Consoli A, Nurjhan N, Capani F, Gerich J 1989 Predominant role of gluconeogenesis in increased hepatic glucose production in NIDDM. Diabetes 38:550-557
105. Magnusson I, Rothman DL, Katz LD, Shulman RG, Shulman GI 1992 Increased rate of gluconeogenesis in type II diabetes mellitus. A13C nuclear magnetic resonance study. J Clin Invest 90:1323-1327
106. Gastaldelli A, Miyazaki Y, Pettiti M, Buzzigoli E, Mahankali S, Ferrannini E, DeFronzo RA 2004 Separate contribution of diabetes, total fat mass, and fat topography to glucose production, gluconeogenesis, and glycogenolysis. J Clin Endocrinol Metab 89:3914-3921
107. Gerich JE, Lorenzi M, Bier DM, Schneider V, Tsalikian E, Karam JH, Forsham PH 1975 Prevention of human diabetic ketoacidosis by somatostatin. Evidence for an essential role of glucagon. N Engl J Med 292:985-989
108. Gerich JE, Schneider VS, Lorenzi M, Tsalikian E, Karam JH, Bier DM, Forsham PH 1976 Role of glucagon in human diabetic ketoacidosis: studies using somatostatin. Clin Endocrinol (Oxf) 5(Suppl):299S-305S
109. Gerich JE, Lorenzi M, Bier DM, Tsalikian E, Schneider V, Karam JH, Forsham PH 1976 Effects of physiologic levels of glucagon and growth hormone on human carbohydrate and lipid metabolism. Studies involving administration of exogenous hormone during suppression of endogenous hormone secretion with somatostatin. J Clin Invest 57:875-884
110. Lins PE, Wajngot A, Adamson U, Vranic M, Efendic S 1983 Minimal increases in glucagon levels enhance glucose production in man with partial hypoinsulinemia. Diabetes 32:633-636
111. Ward WK, Best JD, Halter JB, Porte Jr D 1984 Prolonged infusion of somatostatin with glucagon replacement increases plasma glucose and glucose turnover in man. J Clin Endocrinol Metab 58: 449-453
112. Sherwin RS, Fisher M, Hendler R, Felig P 1976 Hyperglucagonemia and blood glucose regulation in normal, obese and diabetic subjects. N Engl J Med 294:455-461
113. Sherwin RS, Tamborlane W, Hendler R, Sacca L, DeFronzo RA, Felig P 1977 Influence of glucagon replacement on the hyperglycemic and hyperketonemic response to prolonged somatostatin infusion in normal man. J Clin Endocrinol Metab 45:1104-1107
114. Gerich JE 1977 Somatostatin. Its possible role in carbohydrate homeostasis and the treatment of diabetes mellitus. Arch Intern Med 137:659-666
115. Gerich JE, Schultz TA, Lewis SB, Karam JH 1977 Clinical evaluation of somatostatin as a potential ajunct to insulin in the management of diabetes mellitus. Diabetologia 13:537-544
116. Bomboy JD, Lewis SB, Sinclair-Smith BC, Lacy WW, Liljenquist JE 1977 Insulin-glucagon interaction in controlling splanchnic glucose production in normal man. J Clin Endocrinol Metab 44:474-480
117. Mitrakou A, Kelley D, Mokan M, Veneman T, Pangburn T, Reilly J, Gerich J 1992 Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N Engl J Med 326:22-29
118. Taylor K, Kim D, Nielsen LL, Aisporna M, Baron AD, Fineman MS 2005 Day-long subcutaneous infusion of exenatide lowers glycemia in patients with type 2 diabetes. Horm Metab Res 37:627-632
119. Mitrakou A, Kelley D, Veneman T, Jenssen T, Pangburn T, Rei, lly J, Gerich J 1990 Contribution of abnormal muscle and liver glucose metabolism to postprandial hyperglycemia in NIDDM. Diabetes 39:1381-1390
120. DeFronzo RA, Ferrannini E, Hendler R, Wahren J, Felig P 1978 Influence of hyperinsulinemia, hyperglycemia, and the route of glucose administration on splanchnic glucose exchange. Proc Natl Acad Sci USA 75:5173-5177
121. Liljenquist JE, Bloomgarden ZT, Cherrington AD, Perry JM, Rabin D 1979 Possible mechanism by which somatostatin-induced glucagon suppression improves glucose tolerance during insulinopaenia in man. Diabetologia 17:139-143
122. Holste LC, Connolly CC, Moore MC, Neal DW, Cherrington AD 1997 Physiological changes in circulating glucagon alter hepatic glucose disposition during portal glucose delivery. Am J Physiol Endocrinol Metab 273:E488-E496
123. Ludvik B, Nolan JJ, Roberts A, Baloga J, Joyce M, Bell JM, Olefsky JM 1997 Evidence for decreased splanchnic glucose uptake after oral glucose administration in non-insulin-dependent diabetes mellitus. J Clin Invest 100:2354-2361
124. Butler PC, Rizza RA 1991 Contribution to postprandial hyperglycemia and effect on initial splanchnic glucose clearance of hepatic glucose cycling in glucose-intolerant or NIDDM patients. Diabetes 40:73-81
125. Shah P, Vella A, Basu A, Basu R, Schwenk WF, Rizza RA 2000 Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 85:4053-4059
126. Shah P, Basu A, Basu R, Rizza R 1999 Impact of lack of suppression of glucagon on glucose tolerance in humans. Am J Physiol 277: E283-E290
127. Dinneen S, Alzaid A, Turk D, Rizza R 1995 Failure of glucagon suppression contributes to postprandial hyperglycaemia in IDDM. Diabetologia 38:337-343
128. Henkel E, Menschikowski M, Koehler C, Leonhardt W, Hanefeld M 2005 Impact of glucagon response on postprandial hyperglycemia in men with impaired glucose tolerance and type 2 diabetes mellitus. Metabolism 54:1168-1173
129. Gin H, Rigalleau V 2000 Post-prandial hyperglycemia, post-prandial hyperglycemia and diabetes. Diabetes Metab 26:265-272
130. Gerich JE 1997 Metabolic abnormalities in impaired glucose tolerance. Metabolism 46:40-43
131. Gerich JE 1981 Physiology of glucagon. Int Rev Physiol 24:243-275
132. Parker JC, Andrews KM, Allen MR, Stock JL, McNeish JD 2002 Glycemic control in mice with targeted disruption of the glucagon receptor gene. Biochem Biophys Res Commun 290:839-843
133. Gelling RW, Du XQ, Dichmann DS, Romer J, Huang H, Cui L, Obici S, Tang B, Holst JJ, Fledelius C, Johansen PB, Rossetti L, Jelicks LA, Serup P, Nishimura E, Charron MJ 2003 Lower blood glucose, hyperglucagonemia, and pancreatic α-cell hyperplasia in glucagon receptor knockout mice. Proc Natl Acad Sci USA 100: 1438-1443
134. Beshara S, Lundqvist H, Sundin J, Lubberink M, Tolmachev V, Valind S, Antoni G, Langstrom B, Danielson BG 1999 Pharmacokinetics and red cell utilization of iron (III) hydroxide-sucrose complex in anaemic patients: a study using positron emission tomography. Br J Haematol 104:296-302
135. Chen M, Gavrilova O, Zhao WQ, Nguyen A, Lorenzo J, Shen L, Nackers L, Pack S, Jou W, Weinstein LS 2005 Increased glucose tolerance and reduced adiposity in the absence of fasting hypoglycemia in mice with liver-specific Gs α-deficiency. J Clin Invest 115:3217-3227
136. Rouille Y, Westermark G, Martin SK, Steiner DF 1994 Proglucagon is processed to glucagon by prohormone convertase PC2 in αTC1-6 cells. Proc Natl Acad Sci USA 91:3242-3246
137. Rouille Y, Bianchi M, Irminger JC, Halban PA 1997 Role of the prohormone convertase PC2 in the processing of proglucagon to glucagon. FEBS Lett 413:119-123
138. Furuta M, Zhou A, Webb G, Carroll R, Ravazzola M, Orci L, Steiner DF 2001 Severe defect in proglucagon processing in islet A-cells of prohormone convertase 2 null mice. J Biol Chem 276: 27197-27202
139. Furuta M, Yano H, Zhou A, Rouille Y, Holst JJ, Carroll R, Ravazzola M, Orci L, Furuta H, Steiner DF 1997 Defective prohormone processing and altered pancreatic islet morphology in mice lacking active SPC2. Proc Natl Acad Sci USA 94:6646-6651
140. Furuta M, Carroll R, Martin S, Swift HH, Ravazzola M, Orci L, Steiner DF 1998 Incomplete processing of proinsulin to insulin accompanied by elevation of Des-31,32 proinsulin intermediates in islets of mice lacking active PC2. J Biol Chem 273:3431-3437
141. Webb GC, Akbar MS, Zhao C, Swift HH, Steiner DF 2002 Glucagon replacement via micro-osmotic pump corrects hypoglycemia and α-cell hyperplasia in prohormone convertase 2 knockout mice. Diabetes 51:398-405
142. Westphal CH, Muller L, Zhou A, Zhu X, Bonner-Weir S, Schambelan M, Steiner DF, Lindberg I, Leder P 1999 The neuroendocrine protein 7B2 is required for peptide hormone processing in vivo and provides a novel mechanism for pituitary Cushing's disease. Cell 96:689-700
143. Boushey RP, Abadir A, Flamez D, Baggio LL, Li Y, Berger V, Marshall BA, Finegood D, Wang TC, Schuit F, Drucker DJ 2003 Hypoglycemia, defective islet glucagon secretion, but normal islet mass in mice with a disruption of the gastrin gene. Gastroenterology 125:1164-1174
144. Kaestner KH 2000 The hepatocyte nuclear factor 3 (HNF3 or FOXA) family in metabolism. Trends Endocrinol Metab 11:281-285
145. Accili D, Arden KC 2004 FoxOs at the crossroads of cellular metabolism, differentiation, and transformation. Cell 117:421-426
146. Kaestner KH, Katz J, Liu Y, Drucker DJ, Schutz G 1999 Inactivation of the winged helix transcription factor HNF3α affects glucose homeostasis and islet glucagon gene expression in vivo. Genes Dev 13:495-504
147. Duttaroy A, Zimliki CL, Gautam D, Cui Y, Mears D, Wess J 2004 Muscarinic stimulation of pancreatic insulin and glucagon release is abolished in m3 muscarinic acetylcholine receptor-deficient mice. Diabetes 53:1714-1720
148. Yamada M, Miyakawa T, Duttaroy A, Yamanaka A, Moriguchi T, Makita R, Ogawa M, Chou CJ, Xia B, Crawley JN, Felder CC, Deng CX, Wess J 2001 Mice lacking the M3 muscarinic acetylcholine receptor are hypophagic and lean. Nature 410:207-212
149. Liang Y, Osborne MC, Monia BP, Bhanot S, Gaarde WA, Reed C, She P, Jetton TL, Demarest KT 2004 Reduction in glucagon receptor expression by an antisense oligonucleotide ameliorates diabetic syndrome in db/db mice. Diabetes 53:410-417
150. Sloop KW, Cao JX, Siesky AM, Zhang HY, Bodenmiller DM, Cox AL, Jacobs SJ, Moyers JS, Owens RA, Showalter AD, Brenner MB, Raap A, Gromada J, Berridge BR, Monteith DK, Porksen N, McKay RA, Monia BP, Bhanot S, Watts LM, Michael MD 2004 Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors. J Clin Invest 113:1571-1581
151. Brand CL, Rolin B, Jorgensen PN, Svendsen I, Kristensen JS, Holst JJ 1994 Immunoneutralization of endogenous glucagon with monoclonal glucagon antibody normalizes hyperglycaemia in moderately streptozotocin-diabetic rats. Diabetologia 37:985-993
152. Brand CL, Jorgensen PN, Svendsen I, Holst JJ 1996 Evidence for a major role for glucagon in regulation of plasma glucose in conscious, nondiabetic, and alloxan-induced diabetic rabbits. Diabetes 45:1076-1083
153. Sorensen H, Brand CL, Neschen S, Holst JJ, Fosgerau K, Nishimura E, Shulman GI 2006 Immunoneutralization of endogenous glucagon reduces hepatic glucose output and improves long-term glycemic control in diabetic ob/ob mice. Diabetes 55:2843-2848
154. Djuric SW, Grihalde N, Lin CW 2002 Glucagon receptor antagonists for the treatment of type II diabetes: current prospects. Curr Opin Invest Drugs 3:1617-1623
155. Jiang G, Zhang BB 2003 Glucagon and regulation of glucose metabolism. Am J Physiol Endocrinol Metab 284:E671-E678
156. Sloop KW, Michael MD, Moyers JS 2005 Glucagon as a target for the treatment of type 2 diabetes. Expert Opin Ther Targets 9:593-600
157. Gerich JE 1976 Metabolic effects of long-term somatostatin infusion in man. Metabolism 25:1505-1507
158. Gerich JE 1981 Somatostatin and diabetes. Am J Med 70:619-626
159. Bosnak M, Dikici B, Dogru O, Davutoglu M, Haspolat K 2002 Somatostatin therapy in the management of resistant diabetic ketoacidosis. Diabetes Care 25:629-630
160. 2005 Sandostatin LAR depot (octreotide acetate for injectable suspension). East Hanover, NJ: Novartis Pharmaceuticals Corp
161. Moller LN, Stidsen CE, Hartmann B, Holst JJ 2003 Somatostatin receptors. Biochim Biophys Acta 1616:1-84
162. Weckbecker G, Lewis I, Albert R, Schmid HA, Hoyer D, Bruns C 2003 Opportunities in somatostatin research: biological, chemical and therapeutic aspects. Nat Rev Drug Discov 2:999-1017
163. Doyle ME, Egan JM 2003 Pharmacological agents that directly modulate insulin secretion. Pharmacol Rev 55:105-131
164. Yang L, Berk SC, Rohrer SP, Mosley RT, Guo L, Underwood DJ, Arison BH, Birzin ET, Hayes EC, Mitra SW, Parmar RM, Cheng K, Wu TJ, Butler BS, Foor F, Pasternak A, Pan Y, Silva M, Freidinger RM, Smith RG, Chapman K, Schaeffer JM, Patchett AA 1998 Synthesis and biological activities of potent peptidomimetics selective for somatostatin receptor subtype 2. Proc Natl Acad Sci USA 95:10836-10841
165. Cejvan K, Coy DH, Efendic S 2003 Intra-islet somatostatin regulates glucagon release via type 2 somatostatin receptors in rats. Diabetes 52:1176-1181
166. Moldovan S, Atiya A, Adrian TE, Kleinman RM, Lloyd K, Olthoff K, Imagawa D, Shevlin L, Coy D, Walsh J 1995 Somatostatin inhibits B-cell secretion via a subtype-2 somatostatin receptor in the isolated perfused human pancreas. J Surg Res 59:85-90
167. Johnson DG, Goebel CU, Hruby VJ, Bregman MD, Trivedi D 1982 Hyperglycemia of diabetic rats decreased by a glucagon receptor antagonist. Science 215:1115-1116
168. Andreu D, Merrifield RB 1987 Glucagon antagonists. Synthesis and inhibitory properties of Asp3-containing glucagon analogs. Eur J Biochem 164:585-590
169. Unson CG, Andreu D, Gurzenda EM, Merrifield RB 1987 Synthetic peptide antagonists of glucagon. Proc Natl Acad Sci USA 84:4083-4087
170. Gysin B, Johnson DG, Trivedi D, Hruby VJ 1987 Synthesis of two glucagon antagonists: receptor binding, adenylate cyclase, and effects on blood plasma glucose levels. J Med Chem 30:1409-1415
171. Zechel C, Trivedi D, Hruby VJ 1991 Synthetic glucagon antagonists and partial agonists. Int J Pept Protein Res 38:131-138
172. Dharanipragada R, Trivedi D, Bannister A, Siegel M, Tourwe D, Mollova N, Schram K, Hruby VJ 1993 Synthetic linear and cyclic glucagon antagonists. Int J Pept Protein Res 42:68-77
173. Unson CG, Gurzenda EM, Merrifield RB 1989 Biological activities of des-His1[Glu9]glucagon amide, a glucagon antagonist. Peptides 10:1171-1177
174. Hruby VJ 1982 Structure-conformation-activity studies of glucagon and semi-synthetic glucagon analogs. Mol Cell Biochem 44: 49-64
175. Van Tine BA, Azizeh BY, Trivedi D, Phelps JR, Houslay MD, Johnson DG, Hruby VJ 1996 Low level cyclic adenosine 3′,5′-monophosphate accumulation analysis of [des-His1, des- Phe6, Glu9] glucagon-NH2 identifies glucagon antagonists from weak partial agonists/antagonists. Endocrinology 137:3316-3322
176. Azizeh BY, Van Tine BA, Trivedi D, Hruby VJ 1997 Pure glucagon antagonists: biological activities and cAMP accumulation using phosphodiesterase inhibitors. Peptides 18:633-641
177. Ahn JM, Medeiros M, Trivedi D, Hruby VJ 2001 Development of potent glucagon antagonists: structure-activity relationship study of glycine at position 4. J Pept Res 58:151-158
178. Ahn JM, Medeiros M, Trivedi D, Hruby VJ 2001 Development of potent truncated glucagon antagonists. J Med Chem 44:1372-1379
179. Dallas-Yang Q, Shen X, Strowski M, Brady E, Saperstein R, Gibson RE, Szalkowski D, Qureshi SA, Candelore MR, Fenyk-Melody JE, Parmee ER, Zhang BB, Jiang G 2004 Hepatic glucagon receptor binding and glucose-lowering in vivo by peptidyl and non-peptidyl glucagon receptor antagonists. Eur J Pharmacol 501: 225-234
180. Ling A 2002 Small molecule glucagon receptor antagonists. Drugs Future 27:987-993
181. Madsen P, Brand CL, Holst JJ, Knudsen B 1999 Advances in non-peptide glucagon receptor antagonists. Curr Pharm Des 5:683-691
182. Madsen P, Knudsen LB, Wiberg FC, Carr RD 1998 Discovery and structure-activity relationship of the first non-peptide competitive human glucagon receptor antagonists. J Med Chem 41:5150-5157
183. Ling A, Plewe M, Gonzalez J, Madsen P, Sams CK, Lau J, Gregor V, Murphy D, Teston K, Kuki A, Shi S, Truesdale L, Kiel D, May J, Lakis J, Anderes K, Iatsimirskaia E, Sidelmann UG, Knudsen LB, Brand CL, Polinsky A 2002 Human glucagon receptor antagonists based on alkylidene hydrazides. Bioorg Med Chem Lett 12:663-666
184. Ling A, Hong Y, Gonzalez J, Gregor V, Polinsky A, Kuki A, Shi S, Teston K, Murphy D, Porter J, Kiel D, Lakis J, Anderes K, May J, Knudsen LB, Lau J 2001 Identification of alkylidene hydrazides as glucagon receptor antagonists. J Med Chem 44:3141-3149
185. Madsen P, Ling A, Plewe M, Sams CK, Knudsen LB, Sidelmann UG, Ynddal L, Brand CL, Andersen B, Murphy D, Teng M, Truesdale L, Kiel D, May J, Kuki A, Shi S, Johnson MD, Teston KA, Feng J, Lakis J, Anderes K, Gregor V, Lau J 2002 Optimization of alkylidene hydrazide based human glucagon receptor antagonists. Discovery of the highly potent and orally available 3-cyano-4-hydroxybenzoic acid [1-(2,3,5,6-tetramethylbenzyl)-1H-indol-4- ylmethylene] hydrazide. J Med Chem 45:5755-5775
186. Cascieri MA, Koch GE, Ber E, Sadowski SJ, Louizides D, de Laszlo SE, Hacker C, Hagmann WK, MacCoss M, Chicchi GG, Vicario PP 1999 Characterization of a novel, non-peptidyl antagonist of the human glucagon receptor. J Biol Chem 274:8694-8697
187. de Laszlo SE, Hacker C, Li B, Kim D, MacCoss M, Mantlo N, Pivnichny JV, Colwell L, Koch GE, Cascieri MA, Hagmann WK 1999 Potent, orally absorbed glucagon receptor antagonists. Bioorg Med Chem Lett 9:641-646
188. Ladouceur GH, Cook JH, Doherty EM, Schoen WR, MacDougall ML, Livingston JN 2002 Discovery of 5-hydroxyalkyl-4-phenylpyridines as a new class of glucagon receptor antagonists. Bioorg Med Chem Lett 12:461-464
189. Ladouceur GH, Cook JH, Hertzog DL, Jones JH, Hundertmark T, Korpusik M, Lease TG, Livingston JN, MacDougall ML, Osterhout MH, Phelan K, Romero RH, Schoen WR, Shao C, Smith RA 2002 Integration of optimized substituent patterns to produce highly potent 4-aryl-pyridine glucagon receptor antagonists. Bioorg Med Chem Lett 12:3421-3424
190. Petersen KF, Sullivan JT 2001 Effects of a novel glucagon receptor antagonist (Bay 27-9955) on glucagon-stimulated glucose production in humans. Diabetologia 44:2018-2024
191. Chang LL, Sidler KL, Cascieri MA, de LS, Koch G, Li B, MacCoss M, Mantlo N, O'Keefe S, Pang M, Rolando A, Hagmann WK 2001 Substituted imidazoles as glucagon receptor antagonists. Bioorg Med Chem Lett 11:2549-2553
192. Qureshi SA, Rios CM, Xie D, Yang X, Tota LM, Ding VD, Li Z, Bansal A, Miller C, Cohen SM, Jiang G, Brady E, Saperstein R, Duffy JL, Tata JR, Chapman KT, Moller DE, Zhang BB 2004 A novel glucagon receptor antagonist inhibits glucagon-mediated biological effects. Diabetes 53:3267-3273
193. Shen DM, Zhang F, Brady EJ, Candelore MR, las-Yang Q, Ding VD, Dragovic J, Feeney WP, Jiang G, McCann PE, Mock S, Qureshi SA, Saperstein R, Shen X, Tamvakopoulos C, Tong X, Tota LM, Wright MJ, Yang X, Zheng S, Chapman KT, Zhang BB, Tata JR, Parmee ER 2005 Discovery of novel, potent, and orally active spiro-urea human glucagon receptor antagonists. Bioorg Med Chem 15:4564-4569
194. Cohen SM, Duffy JL, Miller C, Kirk BA, Candelore MR, Ding VD, Kaczorowski G, Tota LM, Werrmann JG, Wright M, Parmee ER, Tata JR, Zhang BB 2006 Direct observation (NMR) of the efficacy of glucagon receptor antagonists in murine liver expressing the human glucagon receptor. Bioorg Med Chem 14:1506-1517
195. Kieffer TJ, Habener JF 1999 The glucagon-like peptides. Endocr Rev 20:876-913
196. Bell GI, Sanchez-Pescador R, Laybourn PJ, Najarian RC 1983 Exon duplication and divergence in the human preproglucagon gene. Nature 304:368-371
197. Holst JJ, Ørskov C, Nielsen OV, Schwartz TW 1987 Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut. FEBS Lett 211:169-174
198. Ørskov C, Wettergren A, Holst JJ 1993 Biological effects and metabolic rates of glucagonlike peptide-1 7-36 amide and glucagonlike peptide-1 7-37 in healthy subjects are indistinguishable. Diabetes 42:658-661
199. Kreymann B, Williams G, Ghatei MA, Bloom SR 1987 Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 2:1300-1304
200. Dunning BE, Foley JE, Ahrén B 2005 α-Cell function in health and disease: influence of glucagon-like peptide-1. Diabetologia 48:1700-1713
201. Ritzel R, Ørskov C, Holst JJ, Nauck MA 1995 Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers. Dose-response- relationships. Diabetologia 38:720-725
202. Nauck MA, Heimesaat MM, Behle K, Holst JJ, Nauck MS, Ritzel R, Hufner M, Schmiegel WH 2002 Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab 87:1239-1246
203. Gutniak M, Ørskov C, Holst JJ, Ahrén B, Efendic S 1992 Antidiabetogenic effect of glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetes mellitus. N Engl J Med 326:1316-1322
204. Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Ørskov C, Ritzel R, Schmiegel WH 1997 Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol Endocrinol Metab 273:E981-E988
205. Zander M, Madsbad S, Madsen JL, Holst JJ 2002 Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study. Lancet 359:824-830
206. Ahrén B, Schmitz O 2004 GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes. Horm Metab Res 36:867-876
207. Arulmozhi DK, Portha B 2006 GLP-1 based therapy for type 2 diabetes. Eur J Pharm Sci 28:96-108
208. Edwards CM 2005 The GLP-1 system as a therapeutic target. Ann Med 37:314-322
209. Gautier JF, Fetita S, Sobngwi E, Salaun-Martin C 2005 Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes. Diabetes Metab 31:233-242
210. Hansotia T, Drucker DJ 2005 GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice. Regul Pept 128:125-134
211. Holst JJ 2004 On the physiology of GIP and GLP-1. Horm Metab Res 36:747-754
212. Thorens B 2004 Physiology of GLP-1: lessons from glucoincretin receptor knockout mice. Horm Metab Res 36:766-770
213. Urusova IA, Farilla L, Hui H, D'Amico E, Perfetti R 2004 GLP-1 inhibition of pancreatic islet cell apoptosis. Trends Endocrinol Metab 15:27-33
214. Valverde I, Villanueva-Penacarrillo ML, Malaisse WJ 2002 Pancreatic and extrapancreatic effects of GLP-1. Diabetes Metab 28: 3S85-3S89
215. Mentlein R, Gallwitz B, Schmidt WE 1993 Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 214:829-835
216. 2005 Byetta (exenatide injection)[prescribing information]. San Diego: Amylin Pharmaceuticals, Inc.
217. Ahrén B 2005 Exenatide: a novel treatment of type 2 diabetes. Therapy 2:207-222
218. Keating GM 2005 Exenatide. Drugs 65:1681-1692
219. Schnabel CA 2005 The incretin mimetic, exenatide: a novel treatment option for type 2 diabetes. Br J Diab Vasc Dis 5:227-235
220. Triplitt C, DeFronzo RA 2005 Exenatide: a viewpoint by Curtis Triplitt and Ralph A. DeFronzo. Drugs 65:1693-1695
221. Barnett AH 2005 Exenatide. Drugs Today (Barc) 41:563-578
222. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD 2004 Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 27:2628-2635
223. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD 2005 Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28:1092-1100
224. Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS, Baron AD 2005 Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 28:1083-1091
225. Nielsen LL, Young AA, Parkes DG 2004 Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept 117:77-88
226. Degn KB, Brock B, Juhl CB, Djurhuus CB, Grubert J, Kim D, Han J, Taylor K, Fineman M, Schmitz O 2004 Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia. Diabetes 53:2397-2403
227. Ryan AS, Egan JM, Habener JF, Elahi D 1998 Insulinotropic hormone glucagon-like peptide-1-(7-37) appears not to augment insulin-mediated glucose uptake in young men during euglycemia. J Clin Endocrinol Metab 83:2399-2404
228. Kolterman OG, Buse JB, Fineman MS, Gaines E, Heintz S, Bicsak TA, Taylor K, Kim D, Aisporna M, Wang Y, Baron AD 2003 Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 88:3082-3089
229. Dupre J, Behme MT, McDonald TJ 2004 Exendin-4 normalized postcibal glycemic excursions in type 1 diabetes. J Clin Endocrinol Metab 89:3469-3473
230. Agerso H, Jensen LB, Elbrond B, Rolan P, Zdravkovic M 2002 The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia 45:195-202
231. Elbrond B, Jakobsen G, Larsen S, Agerso H, Jensen LB, Rolan P, Sturis J, Hatorp V, Zdravkovic M 2002 Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects. Diabetes Care 25:1398-1404
232. Madsbad S, Schmitz O, Ranstam J, Jakobsen G, Matthews DR 2004 Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. Diabetes Care 27:1335-1342
233. Herrington DM, Howard TD 2003 From presumed benefit to potential harm: hormone therapy and heart disease. N Engl J Med 349:519-521
234. Juhl CB, Hollingdal M, Sturis J, Jakobsen G, Agerso H, Veldhuis J, Porksen N, Schmitz O 2002 Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes. Diabetes 51:424-429
235. Degn KB, Juhl CB, Sturis J, Jakobsen G, Brock B, Chandramouli V, Rungby J, Landau BR, Schmitz O 2004 One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and α- and β-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes 53:1187-1194
236. Baggio LL, Drucker DJ 2006 Therapeutic approaches to preserve islet mass in type 2 diabetes. Annu Rev Med 57:265-281
237. Drucker DJ 2001 Development of glucagon-like peptide-1-based pharmaceuticals as therapeutic agents for the treatment of diabetes. Curr Pharm Des 7:1399-1412
238. Al-Omar MA, Al-Arifi MN 2005 Glucagon-like peptide-1 derivatives and dipeptidyl peptidase-IV inhibitors. New hope for the treatment of type-2 diabetes. Saudi Med J 26:1511-1515
239. Deacon CF, Ahrén B, Holst JJ 2004 Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of type 2 diabetes? Expert Opin Invest Drugs 13:1091-1102
240. Demuth H-U, McIntosh CH, Pederson RA 2005 Type 2 diabetes - therapy with dipeptidyl peptidase IV inhibitors. Biochim Biophys Acta 1751:33-44
241. Drucker DJ 2003 Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes. Expert Opin Invest Drugs 12:87-100
242. Evans DM 2002 Dipeptidyl peptidase IV inhibitors. IDrugs 5:577-585
243. Holst JJ, Deacon CF 1998 Inhibition of the activity of dipeptidylpeptidase IV as a treatment for type 2 diabetes. Diabetes 47:1663-1670
244. Lambeir AM, Durinx C, Scharpe S, De Meester I 2003 Dipeptidylpeptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci 40:209-294
245. McIntosh CH, Demuth HU, Kim SJ, Pospisilik JA, Pederson RA 2006 Applications of dipeptidyl peptidase IV inhibitors in diabetes mellitus. Int J Biochem Cell Biol 38:860-872
246. Mentlein R 2005 Therapeutic assessment of glucagon-like peptide-1 agonists compared with dipeptidyl peptidase IV inhibitors as potential antidiabetic drugs. Expert Opin Invest Drugs 14:57-64
247. Mest HJ, Mentlein R 2005 Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes. Diabetologia 48:616-620
248. Pratley RE, Salsali A 2005 Dipeptidyl peptidase-4 inhibition in type 2 diabetes mellitus. Sci Med 10:13-15
249. Sinclair EM, Drucker DJ 2005 Glucagon-like peptide 1 receptor agonists and dipeptidyl peptidase IV inhibitors: new therapeutic agents for the treatment of type 2 diabetes. Curr Opin Endocrinol Diabet 12:146-151
250. Triplitt C, Wright A, Chiquette E 2006 Incretin mimetics and dipeptidyl peptidase-IV inhibitors: potential new therapies for type 2 diabetes mellitus. Pharmacotherapy 26:360-374
251. Weber AE 2004 Dipeptidyl peptidase IV inhibitors for the treatment of diabetes. J Med Chem 47:4135-4141
252. Wiedeman PE, Trevillyan JM 2003 Dipeptidyl peptidase IV inhibitors for the treatment of impaired glucose tolerance and type 2 diabetes. Curr Opin Invest Drugs 4:412-420
253. Basu A, Alzaid A, Dinneen S, Caumo A, Cobelli C, Rizza RA 1996 Effects of a change in the pattern of insulin delivery on carbohydrate tolerance in diabetic and nondiabetic humans in the presence of differing degrees of insulin resistance. J Clin Invest 97:2351-2361
254. Villhauer EB, Coppola GM, Hughes TE 2001 DPP-IV inhibition and therapeutic potential. Annu Rep Med Chem 36:191-200
255. Nauck MA, Bartels E, Ørskov C, Ebert R, Creutzfeldt W 1993 Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab 76:912-917
256. Vilsbøll T, Krarup T, Madsbad S, Holst JJ 2003 Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. Regul Pept 114:115-121
257. Meier JJ, Gallwitz B, Siepmann N, Holst JJ, Deacon CF, Schmidt WE, Nauck MA 2003 Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia. Diabetologia 46:798-801
258. Mentlein R 1999 Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul Pept 85:9-24
259. Reinhold D, Kahne T, Steinbrecher A, Wrenger S, Neubert K, Ansorge S, Brocke S 2002 The role of dipeptidyl peptidase IV (DP IV) enzymatic activity in T cell activation and autoimmunity. Biol Chem 383:1133-1138
260. Lankas GR, Leiting B, Roy RS, Eiermann GJ, Beconi MG, Biftu T, Chan CC, Edmondson S, Feeney WP, He H, Ippolito DE, Kim D, Lyons KA, Ok HO, Patel RA, Petrov AN, Pryor KA, Qian X, Reigle L, Woods A, Wu JK, Zaller D, Zhang X, Zhu L, Weber AE, Thornberry NA 2005 Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes 54:2988-2994
261. Takasaki K, Iwase M, Nakajima T, Ueno K, Nomoto Y, Nakanishi S, Higo K 2004 K579, a slow-binding inhibitor of dipeptidyl peptidase IV, is a long-acting hypoglycemic agent. Eur J Pharmacol 486:335-342
262. Sakashita H, Akahoshi F, Kitajima H, Tsutsumiuchi R, Hayashi Y 2006 [(S)-γ-(Arylamino)prolyl]thiazolidine compounds as a novel series of potent and stable DPP-IV inhibitors. Bioorg Med Chem 14:3662-3671
263. Sakashita H, Kitajima H, Nakamura M, Akahoshi F, Hayashi Y 2005 1-((S)-γ-substituted prolyl)-(S)-2-cyanopyrrolidine as a novel series of highly potent DPP-IV inhibitors. Bioorg Med Chem Lett 15:2441-2445
264. Deacon CF 2005 MK-431 (Merck). Curr Opin Invest Drugs 6:419-426
265. Kim D, Wang L, Beconi M, Eiermann GJ, Fisher MH, He H, Hickey GJ, Kowalchick JE, Leiting B, Lyons K, Marsilio F, McCann ME, Patel RA, Petrov A, Scapin G, Patel SB, Roy RS, Wu JK, Wyvratt MJ, Zhang BB, Zhu L, Thornberry NA, Weber AE 2005 (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4] triazolo[4,3-a]pyrazin -7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 48:141-151
266. Villhauer EB, Brinkman JA, Naderi GB, Burkey BF, Dunning BE, Prasad K, Mangold BL, Russell ME, Hughes TE 2003 1-[[(3-hydroxy-1-adamantyl)amino] acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem 46:2774-2789
267. Burkey BF, Li X, Bolognese L, Balkan B, Mone M, Russell M, Hughes TE, Wang PR 2005 Acute and chronic effects of the incretin enhancer vildagliptin in insulin resistant rats. J Pharmacol Exp Ther 315:688-695
268. Augeri DJ, Robl JA, Betebenner DA, Magnin DR, Khanna A, Robertson JG, Wang A, Simpkins LM, Taunk P, Huang Q, Han SP, bboa-Offei B, Cap M, Xin L, Tao L, Tozzo E, Welzel GE, Egan DM, Marcinkeviciene J, Chang SY, Biller SA, Kirby MS, Parker RA, Hamann LG 2005 Discovery and preclinical profile of saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 48:5025-5037
269. Pospisilik JA, Stafford SG, Demuth HU, Brownsey R, Parkhouse W, Finegood DT, McIntosh CH, Pederson RA 2002 Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and β-cell glucose responsiveness in VDF (fa/fa) Zucker rats. Diabetes 51:943-950
270. Pospisilik JA, Stafford SG, Demuth HU, McIntosh CH, Pederson RA 2002 Long-term treatment with dipeptidyl peptidase IV inhibitor improves hepatic and peripheral insulin sensitivity in the VDF Zucker rat: a euglycemic-hyperinsulinemic clamp study. Diabetes 51:2677-2683
271. Ashworth DM, Atrash B, Baker GR, Baxter AJ, Jenkins PD, Jones DM, Szelke M 1996 2-Cyanopyrrolidides as potent, stable inhibitors of dipeptidyl peptidase IV. Bioorg Med Chem Lett 6:1163-1166
272. Gill I, Patel R 2005 Biocatalytic ammonolysis of (5S)-4,5-dihydro-1H-pyrrole-1,5-dicarboxylic acid, 1-(1,1-dimethylethyl)- 5-ethyl ester: preparation of an intermediate to the dipeptidyl peptidase IV inhibitor Saxagliptin. Bioorg Med Chem Lett 16:705-709
273. Kim KR, Rhee SD, Kim HY, Jung WH, Yang SD, Kim SS, Ahn JH, Cheon HG 2005 KR-62436, 6-{2-[2-(5-cyano-4,5-dihydropyrazol-1-yl)-2-oxoethylamino] ethylamino}nicot inonitrile, is a novel dipeptidyl peptidase-IV (DPP-IV) inhibitor with anti-hyperglycemic activity. Eur J Pharmacol 518:63-70
274. Sudre B, Broqua P, White RB, Ashworth D, Evans DM, Haigh R, Junien JL, Aubert ML 2002 Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male Zucker diabetic fatty rats. Diabetes 51:1461-1469
275. Takasaki K, Nakajima T, Ueno K, Nomoto Y, Higo K 2004 Effects of combination treatment with dipeptidyl peptidase IV inhibitor and sulfonylurea on glucose levels in rats. J Pharmacol Sci 95:291-293
276. Takasaki K, Takada H, Nakajima T, Ueno K, Ushiki J, Higo K 2004 Involvement of the active metabolites in the inhibitory activity of K579 on rat plasma dipeptidyl peptidase IV. Eur J Pharmacol 505:237-241
277. Pospisilik JA, Martin J, Doty T, Ehses JA, Pamir N, Lynn FC, Piteau S, Demuth HU, McIntosh CH, Pederson RA 2003 Dipeptidyl peptidase IV inhibitor treatment stimulates β-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes 52:741-750
278. Wargent E, Stocker C, Augstein P, Heinke P, Meyer A, Hoffmann T, Subramanian A, Sennitt MV, Demuth HU, Arch JR, Cawthorne MA 2005 Improvement of glucose tolerance in Zucker diabetic fatty rats by long-term treatment with the dipeptidyl peptidase inhibitor P32/98: comparison with and combination with rosiglitazone. Diabetes Obes Metab 7:170-181
279. Balkan B, Kwasnik L, Miserendino R, Holst JJ, Li X 1999 Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats. Diabetologia 42:1324-1331
280. Mitani H, Takimoto M, Kimura M 2002 Dipeptidyl peptidase IV inhibitor NVP-DPP728 ameliorates early insulin response and glucose tolerance in aged rats but not in aged Fischer 344 rats lacking its enzyme activity. Jpn J Pharmacol 88:451-458
281. Villhauer EB, Brinkman JA, Naderi GB, Dunning BE, Mangold BL, Mone MD, Russell ME, Weldon SC, Hughes TE 2002 1-[2-[(5-Cyanopyridin-2-yl)amino] ethylamino]acetyl-2-(S)-pyrrolidinecarbon itrile: a potent, selective,andorally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem 45:2362-2365
282. Hughes TE, Mone MD, Russell ME, Weldon SC, Villhauer EB 1999 NVP-DPP728 (1-[[[2-[(5-cyanopyridin-2-yl)amino]ethyl]amino] acetyl]-2-cyano-(S)- pyrrolidine), a slow-binding inhibitor of dipeptidyl peptidase IV. Biochemistry 38:11597-11603
283. Mitani H, Takimoto M, Hughes TE, Kimura M 2002 Dipeptidyl peptidase IV inhibition improves impaired glucose tolerance in high-fat diet-fed rats: study using a Fischer 344 rat substrain deficient in its enzyme activity. Jpn J Pharmacol 88:442-450
284. Ahrén B, Simonsson E, Larsson H, Landin-Olsson M, Torgeirsson H, Jansson PA, Sandqvist M, Bavenholm P, Efendic S, Eriksson JW, Dickinson S, Holmes D 2002 Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care 25:869-875
285. Ahrén B, Landin-Olsson M, Jansson P-A, Svenson M, Holmes D, Schweizer A 2004 Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 89:2078-2084
286. Mari A, Sallas WM, He YL, Watson C, Ligueros-Saylan M, Dunning BE, Deacon CF, Holst JJ, Foley JE 2005 Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed β-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab 90:4888-4894
287. Matikainen N, Mänttäri S, Schweizer A, Ulvestad A, Mills D, Dunning BE, Foley JE, Taskinen M-R 2006 Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia 49:2049-2057
288. Balas B, Baig MR, Watson C, Dunning BE, Ligueros-Saylan M, Wang Y, He YL, Darland C, Holst JJ, Deacon CF, Cusi K, Mari A, Foley JE, DeFronzo RA, The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single dose administration in type 2 diabetic patients. J Clin Endocrinol Metab, in press
289. Mari A, Tura A, Gastaldelli A, Ferrannini E 2002 Assessing insulin secretion by modeling in multiple-meal tests: role of potentiation. Diabetes 51(Suppl 1):S221-S226
290. Pratley RE, Jauffret-Kamel S, Galbreath E, Holmes D 2006 Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. Horm Metab Res 38:423-428
291. Ristic S, Byiers S, Foley J, Holmes D 2005 Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response. Diabetes Obes Metab 7:692-698
292. Rosenstock J, Baron MA, Dejager S, Mills D, Schweizer A 2007 Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Care 30:217-223
293. Dejager S, Razac S, Foley JE, Schweizer A, Vildagliptin in drug-naive patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study. Horm Metab Res, in press
294. Ahrén B, Gomis R, Standl E, Mills D, Schweizer A 2004 Twelve-and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 27:2874-2880
295. Bosi E, Camisasca RP, Collober C, Rochotte E, Garber AJ, Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care, in press
296. Rosenstock J, Baron MA, Camisasca RP, Cressier F, Couturier A, Dejager S, Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared to component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab, in press
297. Garber AJ, Schweizer A, Baron MA, Rochotte E, Dejager S, Vildagliptin in combination with pioglitazone improves glycemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes Obes Metab, in press
298. Bergman AJ, Stevens C, Zhou Y, Yi B, Laethem M, de Smet M, Snyder K, Hilliard D, Tanaka W, Zeng W, Tanen M, Wang AQ, Chen L, Winchell G, Davies MJ, Ramael S, Wagner JA, Herman GA 2006 Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. Clin Ther 28:55-72
299. Herman GA, Stevens C, Van DK, Bergman A, Yi B, De SM, Snyder K, Hilliard D, Tanen M, Tanaka W, Wang AQ, Zeng W, Musson D, Winchell G, Davies MJ, Ramael S, Gottesdiener KM, Wagner JA 2005 Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther 78:675-688
300. Herman GA, Bergman A, Stevens C, Kotey P, Yi B, Zhao P, Dietrich B, Golor G, Schrodter A, Keymeulen B, Lasseter KC, Kipnes MS, Snyder K, Hilliard D, Tanen M, Cilissen C, De Smet M, De Lepeleire I, Van Dyck K, Wang AQ, Zeng W, Davies MJ, Tanaka W, Holst JJ, Deacon CF, Gottesdiener KM, Wagner JA 2006 Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels following an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab 91:4612-4619
301. Raz I, Hanefeld M, Xu L, Caria C, Williams-Herman D, Khatami H 2006 Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 49:2564-2571
302. Charbonnel B, Karasik A, Liu J, Wu M, Meininger G 2006 Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 29: 2638-2643
303. Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P 2006 Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 28:1556-1568
304. Raju B, Cryer PE 2005 Maintenance of the postabsorptive plasma glucose concentration: insulin or insulin plus glucagon? Am J Physiol Endocrinol Metab 289:E181-E186
305. Williamson JR, Garcia A, Renold AE, Cahill Jr GF 1966 Studies on the perfused rat liver. I. Effects of glucagon and insulin on glucose metabolism. Diabetes 15:183-187
306. Toft I, Gerich JE, Jenssen T 2002 Autoregulation of endogenous glucose production during hyperglucagonemia. Metabolism 51: 1128-1134
307. Raju B, Cryer PE 2005 Mechanism, temporal patterns, and magnitudes of the metabolic responses to the KATP channel agonist diazoxide. Am J Physiol Endocrinol Metab 288:E80-E85